安脱达治疗单一尘螨和多重过敏的变应性鼻炎的疗效分析

Efficacy analysis of Alutard SQ with Dermatophagoides pteronyssinus preparations in monosensitized and polysensitized patients with allergic rhinitis

目的价安脱达特异性免疫治疗(specific immunotherapy SIT)对单一尘螨过敏和多重过敏的过敏性性鼻炎(allergic rhinitis AR)患者的临床疗效。方法选取123例常年性AR患者,根据过敏原皮肤点刺试验结果,将其分为单一尘螨过敏组和多重过敏组,采用安脱达进行SIT,比较接受SIT前、治疗1年后鼻部症状评分和药物评分,分析评价SIT对单一尘螨过敏和多重过敏AR患者的疗效。根据血清屋尘螨s IgE检测结果,分为两组,屋尘螨s IgEⅠ-Ⅲ级组和s IgEⅣ-Ⅵ级组,评价SIT对不同级别血清屋尘螨s IgE过敏性鼻炎患者的疗效。结果 123例常年性AR患者中,单一过敏组65例,SIT后显效28例,有效31例,无效6例,总有效率(有效率+显效率)为90.8%;多重过敏组58例,治疗后显效27例,有效25例,无效6例,总有效率为89.7%,两组间疗效的差异无统计学意义(P>0.05)。血清屋尘螨s IgEⅠ-Ⅲ级组29例,SIT后总有效13例,无效16例;血清屋尘螨s IgEⅣ-Ⅵ级组94例,治疗后总有效88例,无效6例。血清屋尘螨s IgEⅣ-Ⅵ级组疗效显著高于s IgEⅠ-Ⅲ级患者,两组间疗效差异有统计学意义(P<0.05)。结论安脱达治疗单一尘螨过敏和多重过敏的AR患者的临床疗效相当,可以应用于临床治疗单一尘螨和多重过敏的AR患者。

Objective To evaluate the efficacy of Alutard SQ with standardized Dermatophagoides pteronyssinus preparations in monosensitized and polysensitized patients with allergic rhinitis. Methods 123 dust mites allergic perennial allergic rhinitis patients were selected and divided into monosensitized and polysensitized patientsaccording to the results of allergen skin prick test.Using Alutard SQ for specificimmune therapy, comparing nasal symptom scores and drug scores before and after 1 year of the specificimmune therapy of Alutard SQ, and to analyze and evaluate efficacy of Alutard SQ to memonosensitized and polysensitized patients.According to the results of sIgE in serum of house dust mite, patients were divided into two groups, the sIgEⅠ-Ⅲgroup and sIgE Ⅳ-Ⅵ group, and the effect of SIT in different levels of serum mite sIgE allergic rhinitis was evaluated. Results There were 65 cases of monosensitized （28 cases were markedly improved after treatment, 31 cases were effective, 6 cases were ineffective, total effective rate （efficiency＋significant efficiency） was 90.8%） and 58 cases of polysensitized （27 cases were markedly improved after treatment, 25 cases were effective, 6 cases were ineffective, the total effective rate was 89.7%）in 123 patients with allergic rhinitis. There was no statistically significant difference in curative effect between the two groups （P〉0.05）.There were 29 cases of sIgEⅠ-Ⅲin serum ,13 cases of SIT were effective, and 16 cases were ineffective. There were 94 cases of sIgE Ⅳ-Ⅵ in serum, 88 cases were effective and 6 cases were ineffcvtive. The therapeutic effect of sIgEⅣ-Ⅵ in serum was significantly higher than that in sIgEⅠ-Ⅲgroup, and the difference was statistically significant （P〈0.05）. The therapeutic effect of sIgEⅣ-Ⅵ in serum was significantly higher than that in sIgEⅠ-Ⅲ group, and the difference was statistically significant （P〈0.05）. Conclusion AAlutard SQ is effective in monosensitized and polysensitized patient with allergic rhinitis and can be used both in the clinical treatment of monosensitized and polysensitized patient with allergic rhinitis.